Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Resource Type
Article
Authors
Mao, Helen ; Gagnon, Luc ; Tran, Steven-Phay ; Khan, Sarwat Tahsin ; Becerra Aquino, Amalia Guadalupe ; Saldaña Montemayor, Edgar Eduardo ; Rivera Martínez, Norma Eréndira ; Bohórquez López, Víctor Casildo ; Simón Campos, J. Abraham ; Pineda Cárdenas, Felipe de Jesús ; Chen, Wei ; Hou, Lihua ; Zhang, Zhe ; Corral, Gonzalo ; López, Eduardo ; Teijeiro, Ricardo ; Alzogaray, Maria F. ; Zaidman, Cesar ; Lopardo, Gustavo ; Goecke, Bernardo ; Feijooó Seoane, Rosa María ; Mahmood, Sayed Faisal ; Khan, Ejaz Ahmed ; Akram, Jayed ; Abbas, Salma ; Salahuddin, Naseem ; Rozhkova, Elena ; Zubkova, Tatyana ; Halperin, Scott A ; Ye, Lingyun ; MacKinnon-Cameron, Donna ; Smith, Bruce ; Cahn, Pedro E ; Ruiz-Palacios, Guillermo M ; Ikram, Aamer ; Lanas, Fernando ; Lourdes Guerrero, M ; Muñoz Navarro, Sergio Raúl ; Sued, Omar ; Lioznov, Dmitry A ; Dzutseva, Vitalina ; Parveen, Ghazala ; Zhu, Fengcai ; Leppan, Laura ; Langley, Joanne M ; Barreto, Luis ; Gou, Jinbo ; Zhu, Tao
Source
In The Lancet 15-21 January 2022 399(10321):237-248
Subject
Primary Research Articles
Language
ISSN
0140-6736